Galmed Pharma Faces Nasdaq Bid Price Deadline
Ticker: GLMD · Form: 6-K · Filed: Mar 19, 2024 · CIK: 1595353
| Field | Detail |
|---|---|
| Company | Galmed Pharmaceuticals LTD. (GLMD) |
| Form Type | 6-K |
| Filed Date | Mar 19, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: listing-compliance, sec-filing, biotech
TL;DR
Galmed Pharma had until March 18, 2024, to get its stock price back above $1.00 or face Nasdaq delisting.
AI Summary
Galmed Pharmaceuticals Ltd. received a letter in September 2023 from Nasdaq indicating it no longer met the minimum bid price requirement of $1.00 per share. The company was required to regain compliance by March 18, 2024. This filing is a report of a foreign private issuer for the month of March 2024.
Why It Matters
Failure to meet Nasdaq's minimum bid price requirement could lead to delisting, impacting the company's liquidity and investor confidence.
Risk Assessment
Risk Level: medium — The company is at risk of delisting from Nasdaq if it cannot meet the minimum bid price requirement, which could negatively impact its stock value and liquidity.
Key Numbers
- $1.00 — Minimum Bid Price (Requirement to remain listed on Nasdaq)
Key Players & Entities
- Galmed Pharmaceuticals Ltd. (company) — Registrant
- Nasdaq (company) — Stock exchange
- $1.00 (dollar_amount) — Minimum bid price requirement
- March 18, 2024 (date) — Compliance deadline
- September 2023 (date) — Date of initial notification
FAQ
Did Galmed Pharmaceuticals Ltd. regain compliance with Nasdaq's minimum bid price requirement by March 18, 2024?
This filing does not state whether compliance was regained by the March 18, 2024 deadline. It only reports the initial notification received in September 2023 and the deadline.
What is the consequence of not meeting the minimum bid price requirement?
The company no longer met the requirement to maintain a minimum bid price of $1.00 per share, which is a condition for listing on Nasdaq.
When did Galmed Pharmaceuticals Ltd. first receive notification about the bid price issue?
Galmed Pharmaceuticals Ltd. received a letter from the Nasdaq Listing Qualifications Staff in September 2023.
What is the filing type and period?
This is a Form 6-K, a Report of Foreign Private Issuer, for the month of March 2024.
What is the company's principal executive office address?
The company's principal executive offices are located at 16 Tiomkin St., Tel Aviv 6578317, Israel.
Filing Stats: 346 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2024-03-19 16:30:13
Key Financial Figures
- $1.00 — ment to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price
Filing Documents
- form6-k.htm (6-K) — 15KB
- 0001493152-24-010476.txt ( ) — 16KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Galmed Pharmaceuticals Ltd. Date: March 19, 2024 By: /s/ Allen Baharaff Allen Baharaff President and Chief Executive Officer